Welcome Back Ethan

Let's make today productive, Pandora has some Suggestions.

000

News Captured

+30this week

New Filings

-02this week

Stock Shortages

+03this week

New Approvals

+04this week

Latest News

The Wall Street Journal

Sandoz pushes deeper into biosimilars as pricing pressure mounts on originators

The Swiss generics giant outlined plans to expand its oncology and immunology copy-biologic portfolio through 2026.

Reuters

EU regulators signal faster reviews for interchangeable insulin biosimilars

Industry groups welcomed draft guidance that could shorten time-to-market for certain follow-on biologics.

Reuters

Novartis oncology pipeline faces new EU competition review

Analysts expect parallel trade and tender rules to weigh on net pricing in key markets next quarter.

The Wall Street Journal

US hospitals tighten formularies on high-cost injectables

Purchasing coalitions said they would prioritize biosimilars where interchangeability data is available.

Reuters

Emerging markets drive double-digit growth for specialty generics

Executives cited Latin America and Southeast Asia as the fastest-expanding regions for complex molecules.

Competitor Momentum

NNovartisHigh

PPfizerHigh

SSun PharmaStable

TTeva PharmaceuticalsLow

RRocheStable

Pipeline & Approval Watch

IL-23 Inhibitor (Novartis)

Phase 3 Results Expected

May 2026

ADC combo (Pfizer)

FDA filing expected

Jun 2026

Biosimilar interchangeability (Sandoz)

Advisory committee

Jul 2026

Oncology bispecific (Roche)

PDUFA window

Q3 2026

Top Earnings Insights

CompanyQ1 earningsGrowth

Roche$16.7B+07 %
Pfizer$14.9B+11 %
Novartis$11.3B+06 %
AbbVie$8.9B+06 %
Teva$3.8B-03 %

Oncology and Biosimilars continued driving strong growth this quarter.

Stock Shortages

INFLECTRA, RETACRIT

Expected End DateMay 2026

ImpactUS Markets

COSENTYX

Expected End DateJun 2026

ImpactEU Markets

teva COPAXONE

Expected End DateJul 2026

ImpactEmerging Markets

ONCOLOGY INJECTABLES

Expected End DateQ3 2026

ImpactUS Markets

AI Strategic Summary

Recent market activity indicates increasing competitive pressure across Oncology, Biosimilars, and US generics. Novartis continues strengthening its late-stage oncology pipeline through strategic acquisitions and R&D expansion, while Pfizer's pricing adjustments may intensify margin pressure across key generic portfolios. Meanwhile, rising supply disruptions in select injectable therapies could create short-term commercial opportunities in EU and US markets.

Top Takeaway

Focus on high-growth biosimilar and specialty therapy segments while closely monitoring competitor pipeline acceleration, pricing shifts, and regulatory approvals across Oncology and Immunology.